← All trials
NCT06965751
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 27, 2025
- Primary completion
- Feb 13, 2026
- Completion date
- May 31, 2026
- First posted
- May 11, 2025
- Last posted
- Sep 24, 2025
- Enrollment
- 32
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of MelbourneLead sponsor
- Syneos HealthCollaborator
- Nucleus Network LtdCollaborator
- University of MelbourneOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.